Saratov JOURNAL of Medical and Scientific Research

Biomarkers of renal damage and immunohistochemical detection of oncogenesis in the surgical treatment of renal cell carcinoma

Year: 2018, volume 14 Issue: №3 Pages: 420-426
Heading: Urology Article type: Original article
Authors: Tarasenko A.l., Rossolovsky A.N., Berezinets O.L., Ponukalin A.N., Medvedeva A.M., Zakharova N.B., Popkov V.M., Maslyakova G.N.
Organization: Saratov State Medical University, I.M. Sechenov First Moscow State Medical University

Objective: to assess the possibility of using markers of renal injury and carcinogenesis as additional criteria for the choice of the method of surgical treatment of RCC and to minimize the risk of development and progression of kidney injury. Material and Methods. 60 patients with morphologically confirmed RCC T1-3M0N0 operated on in the volume of open nephrectomy or laparoscopic nephrectomy or laparoscopic resection and the kidney were examined. Patients were divided into 3 groups: group 1: patients after nephrectomy performed for kidney cancer using traditional surgical technique, group 2: patients after laparoscopic nephrectomy and group 3: after laparoscopic resection of kidney tumor. Before surgical operation, on the 5-7 day and after 1 month, all patients were examined by concentrations of urinary excreted lipocalin 2 (NGAL), and serum concentrations of IL-18, MMP-9 and IGF-1. Renal function was estimated using the calculated GFR equation (CKD-EPI 2009) based on serum creatinine level. Immunohistochemical study of histological preparations of distant tumors on proliferation antibodies (Ki-67, PCNA), apoptosis (BAX, Bcl-2) was performed. Differences in clinical data and clinical variables were compared using Spearman rank correlations and t-test. Results. The studied indices of renal damage of IL-18, NGAL, MMP-9 and IGF-1 both in the early (5-7 days) and later (1 month) postoperative period showed a correlation between the surgical intervention method and the degree of tumor cell differentiation. Conclusion. The levels of biomolecular markers of renal damage (IL-18, NGAL, MMP-9 and IGF-1) correlate with the degree of differentiation in thetumoral cells and functional activity of the remaining renal parenchyma in the postoperative period, but also depend on the individual characteristics of the patient's body. A certain level of expression of MMP-9 and IL-18 with a small tumor size can be a guide to determine the indications for the choice of organ-preserving surgery in patients.

1. Chinello Cl, L'imperio VI, Stella M. The proteomic landscape of renal tumors. Expert Rev Proteomics 2016 Dec; 13 (12): 1103-20
2.FerlayJ,Soerjomataraml,ErvikM,etal.GLOBOCAN2012, cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France; 2014
3. Mosoyan MS. Open, laparoscopic and robot-assisted nephrectomy for localized kidney cancer: what to prefer? Nephrology 2014;18 (6): 76-81
4. Popkov VM, Tarasenko Al, Maslyakova GN, et al. Biomolecular assessment of renal function in various types of surgical treatment of renal cell carcinoma. Saratov Journal of Medical Scientific Research 2017; 13 (1): 73-7
5. Rossolovsky AN, Glybochko PV, Popkov VM, et al. Differentiated approach to renal damage assessment in patients with urolithiasis by noninvasive markers. Saratov Journal of Medical Scientific Research 2010; 6 (3): 708-15
6. Kogan Ml, Ahohov ZM, Gusev AA, Pasechnik DG. Molecular-biological factors predicting the course of renal cell cancer (literature review). Oncourology 2016; 12 (3): 45-51
7. Banyra OB, StroyAA, ShulyakAV. Markers of tumor growth in the diagnosis of kidney cancer. Experimental and clinical urology 2011; 4: 72-8
8. Glybochko PV, Zacharova NB, Ponukalin AN, et al. Diagnostic value of angiogenesis rates in renal-cell carcinoma. Cancer Urology 2011; 7(3): 25-30
9. Rosner МН. Urinary biomarkers for the detection of renal injury. Adv Clin Chem 2009; 49: 73-97
10. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif 2010; 4 (29): 357-65
11. Larsson SC & WolkA. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 2011; 54: 1013-8
12. Zhang L, Xul B, Chen S, et al. The complex roles of microRNAs in the metastasis of renal cell carcinoma. J Nanosci Nanotechnol 2013; 13: 3195-203
13. Wu D, Pan H, Zhou Y, Zhou J. microRNA-133b down regulation and inhibition of cell proliferation, migration and invasion by targeting matrix metallopeptidase-9 in renal cell carcinoma. Mol Med Rep 2014 Jun; 9 (6): 2491-8
14. Kallakury BV, Karikehalli S, Haholu A, et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:311-9
15. Angelina Di Carlo. Evaluation of neutrophil gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in sera and urine of patients with kidney tumors. Oncol Lett 2013 May; 5 (5): 1677-81
16. Sarfstein R, Werner H. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology 2013;154 (5): 1672-9
17. Kjeldsen L. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-32
18. Flower DR, North AC, Sansom CE. The lipocalin protein family: structural and sequence overview. Biochim Biophys Acta 2000, 1482:9-24
19. Rabkin R, Schaefer F. New concepts: growth hormone, insulin-like growth factor-l and the kidney. Growth Horm IGF Res 2004 Aug; 14 (4): 270-6
20. Maslyakova GN, Medvedeva AV Study of aggressivity factors for diagnostics and prognosis of renal tumors course (review). Bulletin of Medical Internet Conferences 2013; 3 (4): 845-8
21. Rebrova OYu. Statistical analysis of medical data: Application software package STATISTICA. Moscow: Media Sphere, 2002; 312 p.

2018_3_420-426.pdf2.05 MB

No votes yet